Pathogenic variants of SLC25A1 are predicted to compromise metabolisms of lipid, sterol synthesis, gluconeogenesis, and glycolysis [416], which somehow leads to the development of CMS. The gene discussed is SLC25A1; the disease is congenital myasthenic syndrome.